NDLI: N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

Please wait, while we are loading the content...

Year: 2017 Volume: 40

Year: 2016 Volume: 39

Year: 2015 Volume: 38

Year: 2014 Volume: 37

Year: 2013 Volume: 36

Year: 2013 Volume: 36 Issue: 6

Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine.

Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature.

Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study.

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

Atypical antipsychotics in the treatment of posttraumatic stress disorder.

Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.

Curcumin as an add-on to antidepressive treatment.

Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India.

Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.

Year: 2013 Volume: 36 Issue: 5

Year: 2013 Volume: 36 Issue: 4

Year: 2013 Volume: 36 Issue: 3

Year: 2013 Volume: 36 Issue: 2

Year: 2013 Volume: 36 Issue: 1

Year: 2012 Volume: 35

Year: 2011 Volume: 34

Year: 2010 Volume: 33

Year: 2009 Volume: 32

Year: 2008 Volume: 31

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Farokhnia, Mehdi Azarkolah, Anita Adinehfar, Forod Khodaie-Ardakani, Mohammad-Reza Hosseini, Seyed-Mohammad-Reza Yekehtaz, Habibeh Tabrizi, Mina Rezaei, Farzin Salehi, Bahman Sadeghi, Seyed-Mohammad-Hossein Moghadam, Marzieh Gharibi, Fardin Mirshafiee, Omid Akhondzadeh, Shahin
Description	Country affiliation: Iran Author Affiliation: Farokhnia M ( *Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences)
Abstract	OBJECTIVES: Despite the burden of negative symptoms on quality of life in schizophrenic patients, no completely effective treatment has been developed to address such symptoms yet. Abnormalities in oxidative stress pathways have been recently demonstrated to be involved in the pathophysiology of schizophrenia, and a growing interest in antioxidant agents is emerging for targeting negative symptoms of schizophrenia. N-Acetylcysteine (NAC) is a potent antioxidant with neuroprotective properties. This study aimed to evaluate the possible effects of NAC as an adjunct to risperidone in treating negative symptoms of schizophrenia. MATERIALS AND METHODS: In this randomized, double-blind, placebo-controlled, parallel-group study, 42 patients with chronic schizophrenia and a score of 20 or greater on the negative subscale of positive and negative syndrome scale (PANSS) were enrolled in the active phase of their illness. The participants were equally randomized to receive NAC (up to 2 g/d) or placebo, in addition to risperidone (up to 6 mg/d) for 8 weeks. The participants were rated using PANSS every 2 weeks, and the decrease of PANSS negative subscale score was considered as our primary outcome. RESULTS: By the study end point, NAC-treated patients showed significantly greater improvement in the PANSS total (P = 0.006) and negative subscale (P < 0.001) scores than that in the placebo group, but this difference was not significant for positive and general psychopathology subscales. There was no significant difference between the 2 groups in the frequency of adverse effects. CONCLUSIONS: NAC add-on therapy showed to be a safe and effective augmentative strategy for alleviating negative symptoms of schizophrenia.
File Format	HTM / HTML
ISSN	03625664
Issue Number	6
Volume Number	36
e-ISSN	1537162X
Journal	Clinical Neuropharmacology
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2013-11-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Psychopharmacology Acetylcysteine Administration & Dosage Antipsychotic Agents Free Radical Scavengers Risperidone Schizophrenia Drug Therapy Schizophrenic Psychology Adult Chronic Disease Double-blind Method Drug Therapy, Combination Female Humans Male Diagnosis Treatment Outcome Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Neurology (clinical) Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in